Abstract
Purpose: The purpose of this study is to describe initial experience with a new continuous flow, ventricular assist device (VAD) in the treatment of patients with end-stage heart failure. Description: The first patient with dilative cardiomyopathy and with end-stage heart failure received Heartware implantation as a bridge to cardiac transplantation at Hue Central Hospital on june 6, 2014. Evaluation: This patient was in terminal heart failure despite inotropic support, and he had a very poor left ventricular ejective fraction of 17%. Heartware implant technique performed by a fixed connection the pump inflow to the apex of left ventricule and a termino-lateral anastomosis for connecting the pump outflow graft to the ascendent aorta. Duration time for set-up the Heartware assist system and device implantation was about 5 hours. It was making a good postoperative progress with the ventilation time of 4 hours. The hemodynamic parameters were improved with an significant increasing cardiac output in comparison with the preoperative period (4.63±0.42 vs 1.67±0.37 L/min, p<0.05); EF (18.23±0.84% vs 17.23±0.64%, p>0.05). The functional signs of renal or hepatic impairment developed with improving the urine quantity (2.92±0.74 vs 0.9±0.29 L/24h, p<0.01); serum creatinine (68.24±14.04 U/L); SGOT (28.42±3.23 U/L); SGPT (28.42±3.23 U/L). The most important thing is the patient having a better quality of life with a minimal medical treatment and unrequired inotropic therapy. The ICU time was 72 hours. He was discharged from hospital 14 days after HVAD implant. Until today, the mechanical circulatory support time was more over one year. The Heartware pump is effectively managed with a minimal speed of 2400 RPM; low power of 3.1±0.5W; and optimal pump flow of 3.8±0.6 L/min. There aren't HVAD post-implant complications such as a thromboembolic event or an infection. Conclusion: It is the first time in Vietnam, the HeartWare implantation has been successfully applied at Hue Central Hospital as a bridge to transplantation in a patient with end-stage heart failure.